Grant: Fellowship - Priority Announcement: Drug Safety and Effectiveness
University of Toronto
$275,000.00
Cardiovascular disease in patients with breast cancer and lymphoma
EF 2012-13
Résumé
Background: Cardiovascular disease is a leading cause of death in cancer patients, and limits their quality of life. It is not well-defined which cancer patients get heart disease after treatment and how it impacts their health.
Objectives:
1. To quantify and describe the type of heart disease in breast cancer and lymphoma patients during cancer treatment, and how this affects their treatment and survival in the 5 years after diagnosis.
2. To quantify and describe the type of heart disease in long term survivors of breast cancer and lymphoma, as the well as the time of development of these events
3. To quantify the impact of heart disease development on the lifespan of cancer survivors and their use of hospital resources
4. To determine which patient characteristics, and which elements of their treatment, can be predictive of who develops heart disease as well as the type of heart disease and its timing
5. Study markers of the quality of care of cancer survivors who develop heart disease and how they compare with other patients with heart disease
6. Particular attention will be paid to the long term effects of trastuzumab, a breast cancer drug which causes heart disease that is thought to be reversible, although its long term effects are unknown
Methods:
The Ontario Cancer Registry will be used to identify patients with breast cancer and lymphoma. The Ontario Health Card number will be used to link these patients with the Canadian Institute of Health Information Discharge Abstract Database, Ontario Registered Persons Database, and the Ontario Drug benefit Database. Trastuzumab use will be identified from the New Drug Funding Program database. We will also consider performing targeted chart reviews of patients who are treated with chemotherapy for breast cancer and lymphoma to obtain details of their cancer treatment. This will allow us to identify patient demographics, baseline comorbidities, medications and subsequent hospitalizations.
Programme
Fellowship - Priority Announcement: Drug Safety and Effectiveness
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
270505
Name
Abdel-Qadir Husam-Eldin M
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Cardiovascular disease in patients with breast cancer and lymphoma
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$275,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Drug Safety and Effectiveness
Keyworddelim
Breast Cancer; Cancer; Cardiomyopathy; Cardiovascular Disease; Coronary Artery Disease; Heart Failure; Lymphoma; Outcome And Process Assessment; Quality Indicators; Trastuzumab
Abstract
Background: Cardiovascular disease is a leading cause of death in cancer patients, and limits their quality of life. It is not well-defined which cancer patients get heart disease after treatment and how it impacts their health.
Objectives:
1. To quantify and describe the type of heart disease in breast cancer and lymphoma patients during cancer treatment, and how this affects their treatment and survival in the 5 years after diagnosis.
2. To quantify and describe the type of heart disease in long term survivors of breast cancer and lymphoma, as the well as the time of development of these events
3. To quantify the impact of heart disease development on the lifespan of cancer survivors and their use of hospital resources
4. To determine which patient characteristics, and which elements of their treatment, can be predictive of who develops heart disease as well as the type of heart disease and its timing
5. Study markers of the quality of care of cancer survivors who develop heart disease and how they compare with other patients with heart disease
6. Particular attention will be paid to the long term effects of trastuzumab, a breast cancer drug which causes heart disease that is thought to be reversible, although its long term effects are unknown
Methods:
The Ontario Cancer Registry will be used to identify patients with breast cancer and lymphoma. The Ontario Health Card number will be used to link these patients with the Canadian Institute of Health Information Discharge Abstract Database, Ontario Registered Persons Database, and the Ontario Drug benefit Database. Trastuzumab use will be identified from the New Drug Funding Program database. We will also consider performing targeted chart reviews of patients who are treated with chemotherapy for breast cancer and lymphoma to obtain details of their cancer treatment. This will allow us to identify patient demographics, baseline comorbidities, medications and subsequent hospitalizations.
Competitiondate
201210
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Abdel-Qadir, Husam-Eldin M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $275,000~ $0~